March 25, 2020
Astellas Pharma and CytomX Therapeutics have formed a strategic collaboration for the US biotech’s novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens for the treatment of cancer, the two companies said on March 24. The deal...read more